» Articles » PMID: 37126938

Uncertainties and Controversies in Axillary Management of Patients with Breast Cancer

Abstract

The aims of this Oncoplastic Breast Consortium and European Breast Cancer Research Association of Surgical Trialists initiative were to identify uncertainties and controversies in axillary management of early breast cancer and to recommend appropriate strategies to address them. By use of Delphi methods, 15 questions were prioritized by more than 250 breast surgeons, patient advocates and radiation oncologists from 60 countries. Subsequently, a global virtual consensus panel considered available data, ongoing studies and resource utilization. It agreed that research should no longer be prioritized for standardization of axillary imaging, de-escalation of axillary surgery in node-positive cancer and risk evaluation of modern surgery and radiotherapy. Instead, expert consensus recommendations for clinical practice should be based on current evidence and updated once results from ongoing studies become available. Research on de-escalation of radiotherapy and identification of the most relevant endpoints in axillary management should encompass a meta-analysis to identify knowledge gaps, followed by a Delphi process to prioritize and a consensus conference to refine recommendations for specific trial designs. Finally, treatment of residual nodal disease after surgery was recommended to be assessed in a prospective register.

Citing Articles

Rare Breast Cancers Review.

Song B, Singh H Healthcare (Basel). 2024; 12(23).

PMID: 39685105 PMC: 11640930. DOI: 10.3390/healthcare12232483.


Association of Breast Cancer Subtypes and Clinicopathological Factors with Axillary Lymph Node Positivity Amongst Women with Breast Cancer in Rajasthan: An Observational Analytical Study.

Patel P, Kumar N, Babu A, Gupta A, Lakhera K, Singh S Indian J Surg Oncol. 2024; 15(4):768-776.

PMID: 39555353 PMC: 11564685. DOI: 10.1007/s13193-024-01987-x.


Identification of sentinel lymph node macrometastasis in breast cancer by deep learning based on clinicopathological characteristics.

Zhang D, Svensson M, Eden P, Dihge L Sci Rep. 2024; 14(1):26970.

PMID: 39505964 PMC: 11541545. DOI: 10.1038/s41598-024-78040-y.


De-Escalation of Axillary Surgery in Clinically Node-Positive Breast Cancer Patients Treated with Neoadjuvant Therapy: Comparative Long-Term Outcomes of Sentinel Lymph Node Biopsy versus Axillary Lymph Node Dissection.

Tinterri C, Barbieri E, Sagona A, Di Maria Grimaldi S, Gentile D Cancers (Basel). 2024; 16(18).

PMID: 39335140 PMC: 11430603. DOI: 10.3390/cancers16183168.


Management of the axilla in breast cancer patients: critical review, regional modified Delphi consensus and implementation in the Tuscan breast network.

Ghilli M, Becherini C, Meattini I, Angiolini C, Bengala C, Marconi A Radiol Med. 2024; 129(6):945-954.

PMID: 38683499 DOI: 10.1007/s11547-024-01818-7.


References
1.
Sackey H, Johansson H, Sandelin K, Liljegren G, MacLean G, Frisell J . Self-perceived, but not objective lymphoedema is associated with decreased long-term health-related quality of life after breast cancer surgery. Eur J Surg Oncol. 2015; 41(4):577-84. DOI: 10.1016/j.ejso.2014.12.006. View

2.
Mansel R, Fallowfield L, Kissin M, Goyal A, Newcombe R, Dixon J . Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006; 98(9):599-609. DOI: 10.1093/jnci/djj158. View

3.
Weber W, Haug M, Kurzeder C, Bjelic-Radisic V, Koller R, Reitsamer R . Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomy. Breast Cancer Res Treat. 2018; 172(3):523-537. PMC: 6245050. DOI: 10.1007/s10549-018-4937-1. View

4.
Banys-Paluchowski M, Gasparri M, de Boniface J, Gentilini O, Stickeler E, Hartmann S . Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps, and Rationale for the EUBREAST-03 AXSANA Study. Cancers (Basel). 2021; 13(7). PMC: 8037995. DOI: 10.3390/cancers13071565. View

5.
Reimer T, Glass A, Botteri E, Loibl S, Gentilini O . Avoiding Axillary Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy in Breast Cancer: Rationale for the Prospective, Multicentric EUBREAST-01 Trial. Cancers (Basel). 2020; 12(12). PMC: 7763449. DOI: 10.3390/cancers12123698. View